If the biotech highlighted in today’s article ends up getting its drug approved, it would be the first Alzheimer’s treatment that actually reduces the cognitive decline of the devastating disease – and the FDA recently indicated that it would give the experimental drug a more speedy review, causing shares of the firm to climb about 9%. For more on the biotech in question and its potential blockbuster Alzheimer’s drug, CLICK HERE.